What we invest in:
MGI Investment Management is dedicated to funding and supporting early-stage biotech startups, with a particular focus on projects that have the potential to deliver breakthough therapies and technologies. We identifies high-impact innovations in Biotechnology and Pharmaceuticals.
Primarily, we focus on the Scandinavian region, a globally recognized hub for life science innovation.
Why we invest:
Our mission is to transform groundbreaking discoveries into commercially viable companies that address unmet medical needs and improve global health.
We believe that early-stage investment in biotech can yield extraordinary financial returns and create significant social impact.
How we invest:
We take an active, hands-on approach from the earliest stages of development, partnering with scientists to de-risk projects and accelerate their journey to market.
Our investment strategy is designed to maximize success, de-risk and scale companies through deep engagement, operational support, and strategic funding.
What we target:
We target high financial returns by focusing on early-stage investment with more than 8x multiple. The rigorous de-risking process, increases the chance of success, alligning with our strategic investment horizon of initial exits after 3-4 years.
Investment Committee
The Investment Committee of MGI Investment Management approves and continuously monitors the investments on behalf of the fund. Collectively, the members have more than 100 years of industry experience in guiding investments toward high-growth and value-creating outcomes.
